

Inactivated Vaccine Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/I54065E0468BEN.html>

Date: January 2022

Pages: 73

Price: US\$ 3,250.00 (Single User License)

ID: I54065E0468BEN

Abstracts

Inactivated vaccines are viruses or bacteria that are first cultured and then inactivated with heat or chemicals. Inactivated vaccines may consist of whole viruses or bacteria, or they may consist of fragments that cleave together to form a cleaved vaccine.

This report contains market size and forecasts of Inactivated Vaccine in Global, including the following market information:

Global Inactivated Vaccine Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Inactivated Vaccine market was valued at 5983.1 million in 2021 and is projected to reach US\$ 7437.9 million by 2028, at a CAGR of 3.2% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Children Inactivated Vaccine Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Inactivated Vaccine include Astellas Pharma(Japan), CSL Limited(Australia), Emergent BioSolutions(U.S.), GlaxoSmithKline(U.K.), Johnson & Johnson(U.S.), MedImmune(U.S.), Merck & Co(U.S.), Pfizer(U.S.) and Sanofi Pasteur(France) and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Inactivated Vaccine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Inactivated Vaccine Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Inactivated Vaccine Market Segment Percentages, by Type, 2021 (%)

Children Inactivated Vaccine

Adult Inactivated Vaccine

Global Inactivated Vaccine Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Inactivated Vaccine Market Segment Percentages, by Application, 2021 (%)

Hospital

Medical Center

Global Inactivated Vaccine Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Inactivated Vaccine Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Inactivated Vaccine revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Inactivated Vaccine revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Astellas Pharma(Japan)

CSL Limited(Australia)

Emergent BioSolutions(U.S.)

GlaxoSmithKline(U.K.)

Johnson & Johnson(U.S.)

MedImmune(U.S.)

Merck & Co(U.S.)

Pfizer(U.S.)

Sanofi Pasteur(France)

Serum Institute of India Pvt(India)

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Inactivated Vaccine Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Inactivated Vaccine Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL INACTIVATED VACCINE OVERALL MARKET SIZE

- 2.1 Global Inactivated Vaccine Market Size: 2021 VS 2028
- 2.2 Global Inactivated Vaccine Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Inactivated Vaccine Players in Global Market
- 3.2 Top Global Inactivated Vaccine Companies Ranked by Revenue
- 3.3 Global Inactivated Vaccine Revenue by Companies
- 3.4 Top 3 and Top 5 Inactivated Vaccine Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Inactivated Vaccine Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Inactivated Vaccine Players in Global Market
 - 3.6.1 List of Global Tier 1 Inactivated Vaccine Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Inactivated Vaccine Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Inactivated Vaccine Market Size Markets, 2021 & 2028

4.1.2 Children Inactivated Vaccine

4.1.3 Adult Inactivated Vaccine

4.2 By Type - Global Inactivated Vaccine Revenue & Forecasts

4.2.1 By Type - Global Inactivated Vaccine Revenue, 2017-2022

4.2.2 By Type - Global Inactivated Vaccine Revenue, 2023-2028

4.2.3 By Type - Global Inactivated Vaccine Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Inactivated Vaccine Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Medical Center

5.2 By Application - Global Inactivated Vaccine Revenue & Forecasts

5.2.1 By Application - Global Inactivated Vaccine Revenue, 2017-2022

5.2.2 By Application - Global Inactivated Vaccine Revenue, 2023-2028

5.2.3 By Application - Global Inactivated Vaccine Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Inactivated Vaccine Market Size, 2021 & 2028

6.2 By Region - Global Inactivated Vaccine Revenue & Forecasts

6.2.1 By Region - Global Inactivated Vaccine Revenue, 2017-2022

6.2.2 By Region - Global Inactivated Vaccine Revenue, 2023-2028

6.2.3 By Region - Global Inactivated Vaccine Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Inactivated Vaccine Revenue, 2017-2028

6.3.2 US Inactivated Vaccine Market Size, 2017-2028

6.3.3 Canada Inactivated Vaccine Market Size, 2017-2028

6.3.4 Mexico Inactivated Vaccine Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Inactivated Vaccine Revenue, 2017-2028

6.4.2 Germany Inactivated Vaccine Market Size, 2017-2028

6.4.3 France Inactivated Vaccine Market Size, 2017-2028

6.4.4 U.K. Inactivated Vaccine Market Size, 2017-2028

6.4.5 Italy Inactivated Vaccine Market Size, 2017-2028

6.4.6 Russia Inactivated Vaccine Market Size, 2017-2028

6.4.7 Nordic Countries Inactivated Vaccine Market Size, 2017-2028

6.4.8 Benelux Inactivated Vaccine Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Inactivated Vaccine Revenue, 2017-2028

6.5.2 China Inactivated Vaccine Market Size, 2017-2028

6.5.3 Japan Inactivated Vaccine Market Size, 2017-2028

6.5.4 South Korea Inactivated Vaccine Market Size, 2017-2028

6.5.5 Southeast Asia Inactivated Vaccine Market Size, 2017-2028

6.5.6 India Inactivated Vaccine Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Inactivated Vaccine Revenue, 2017-2028

6.6.2 Brazil Inactivated Vaccine Market Size, 2017-2028

6.6.3 Argentina Inactivated Vaccine Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Inactivated Vaccine Revenue, 2017-2028

6.7.2 Turkey Inactivated Vaccine Market Size, 2017-2028

6.7.3 Israel Inactivated Vaccine Market Size, 2017-2028

6.7.4 Saudi Arabia Inactivated Vaccine Market Size, 2017-2028

6.7.5 UAE Inactivated Vaccine Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Astellas Pharma(Japan)

7.1.1 Astellas Pharma(Japan) Corporate Summary

7.1.2 Astellas Pharma(Japan) Business Overview

7.1.3 Astellas Pharma(Japan) Inactivated Vaccine Major Product Offerings

7.1.4 Astellas Pharma(Japan) Inactivated Vaccine Revenue in Global Market
(2017-2022)

7.1.5 Astellas Pharma(Japan) Key News

7.2 CSL Limited(Australia)

7.2.1 CSL Limited(Australia) Corporate Summary

7.2.2 CSL Limited(Australia) Business Overview

7.2.3 CSL Limited(Australia) Inactivated Vaccine Major Product Offerings

7.2.4 CSL Limited(Australia) Inactivated Vaccine Revenue in Global Market
(2017-2022)

7.2.5 CSL Limited(Australia) Key News

7.3 Emergent BioSolutions(U.S.)

7.3.1 Emergent BioSolutions(U.S.) Corporate Summary

7.3.2 Emergent BioSolutions(U.S.) Business Overview

- 7.3.3 Emergent BioSolutions(U.S.) Inactivated Vaccine Major Product Offerings
- 7.3.4 Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue in Global Market (2017-2022)
- 7.3.5 Emergent BioSolutions(U.S.) Key News
- 7.4 GlaxoSmithKline(U.K.)
 - 7.4.1 GlaxoSmithKline(U.K.) Corporate Summary
 - 7.4.2 GlaxoSmithKline(U.K.) Business Overview
 - 7.4.3 GlaxoSmithKline(U.K.) Inactivated Vaccine Major Product Offerings
 - 7.4.4 GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue in Global Market (2017-2022)
 - 7.4.5 GlaxoSmithKline(U.K.) Key News
- 7.5 Johnson & Johnson(U.S.)
 - 7.5.1 Johnson & Johnson(U.S.) Corporate Summary
 - 7.5.2 Johnson & Johnson(U.S.) Business Overview
 - 7.5.3 Johnson & Johnson(U.S.) Inactivated Vaccine Major Product Offerings
 - 7.5.4 Johnson & Johnson(U.S.) Inactivated Vaccine Revenue in Global Market (2017-2022)
 - 7.5.5 Johnson & Johnson(U.S.) Key News
- 7.6 MedImmune(U.S.)
 - 7.6.1 MedImmune(U.S.) Corporate Summary
 - 7.6.2 MedImmune(U.S.) Business Overview
 - 7.6.3 MedImmune(U.S.) Inactivated Vaccine Major Product Offerings
 - 7.6.4 MedImmune(U.S.) Inactivated Vaccine Revenue in Global Market (2017-2022)
 - 7.6.5 MedImmune(U.S.) Key News
- 7.7 Merck & Co(U.S.)
 - 7.7.1 Merck & Co(U.S.) Corporate Summary
 - 7.7.2 Merck & Co(U.S.) Business Overview
 - 7.7.3 Merck & Co(U.S.) Inactivated Vaccine Major Product Offerings
 - 7.7.4 Merck & Co(U.S.) Inactivated Vaccine Revenue in Global Market (2017-2022)
 - 7.7.5 Merck & Co(U.S.) Key News
- 7.8 Pfizer(U.S.)
 - 7.8.1 Pfizer(U.S.) Corporate Summary
 - 7.8.2 Pfizer(U.S.) Business Overview
 - 7.8.3 Pfizer(U.S.) Inactivated Vaccine Major Product Offerings
 - 7.8.4 Pfizer(U.S.) Inactivated Vaccine Revenue in Global Market (2017-2022)
 - 7.8.5 Pfizer(U.S.) Key News
- 7.9 Sanofi Pasteur(France)
 - 7.9.1 Sanofi Pasteur(France) Corporate Summary
 - 7.9.2 Sanofi Pasteur(France) Business Overview

7.9.3 Sanofi Pasteur(France) Inactivated Vaccine Major Product Offerings

7.9.4 Sanofi Pasteur(France) Inactivated Vaccine Revenue in Global Market
(2017-2022)

7.9.5 Sanofi Pasteur(France) Key News

7.10 Serum Institute of India Pvt(India)

7.10.1 Serum Institute of India Pvt(India) Corporate Summary

7.10.2 Serum Institute of India Pvt(India) Business Overview

7.10.3 Serum Institute of India Pvt(India) Inactivated Vaccine Major Product Offerings

7.10.4 Serum Institute of India Pvt(India) Inactivated Vaccine Revenue in Global
Market (2017-2022)

7.10.5 Serum Institute of India Pvt(India) Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. Inactivated Vaccine Market Opportunities & Trends in Global Market
- Table 2. Inactivated Vaccine Market Drivers in Global Market
- Table 3. Inactivated Vaccine Market Restraints in Global Market
- Table 4. Key Players of Inactivated Vaccine in Global Market
- Table 5. Top Inactivated Vaccine Players in Global Market, Ranking by Revenue (2021)
- Table 6. Global Inactivated Vaccine Revenue by Companies, (US\$, Mn), 2017-2022
- Table 7. Global Inactivated Vaccine Revenue Share by Companies, 2017-2022
- Table 8. Global Companies Inactivated Vaccine Product Type
- Table 9. List of Global Tier 1 Inactivated Vaccine Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 Inactivated Vaccine Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type – Global Inactivated Vaccine Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type - Inactivated Vaccine Revenue in Global (US\$, Mn), 2017-2022
- Table 13. By Type - Inactivated Vaccine Revenue in Global (US\$, Mn), 2023-2028
- Table 14. By Application – Global Inactivated Vaccine Revenue, (US\$, Mn), 2021 & 2028
- Table 15. By Application - Inactivated Vaccine Revenue in Global (US\$, Mn), 2017-2022
- Table 16. By Application - Inactivated Vaccine Revenue in Global (US\$, Mn), 2023-2028
- Table 17. By Region – Global Inactivated Vaccine Revenue, (US\$, Mn), 2021 & 2028
- Table 18. By Region - Global Inactivated Vaccine Revenue (US\$, Mn), 2017-2022
- Table 19. By Region - Global Inactivated Vaccine Revenue (US\$, Mn), 2023-2028
- Table 20. By Country - North America Inactivated Vaccine Revenue, (US\$, Mn), 2017-2022
- Table 21. By Country - North America Inactivated Vaccine Revenue, (US\$, Mn), 2023-2028
- Table 22. By Country - Europe Inactivated Vaccine Revenue, (US\$, Mn), 2017-2022
- Table 23. By Country - Europe Inactivated Vaccine Revenue, (US\$, Mn), 2023-2028
- Table 24. By Region - Asia Inactivated Vaccine Revenue, (US\$, Mn), 2017-2022
- Table 25. By Region - Asia Inactivated Vaccine Revenue, (US\$, Mn), 2023-2028
- Table 26. By Country - South America Inactivated Vaccine Revenue, (US\$, Mn), 2017-2022
- Table 27. By Country - South America Inactivated Vaccine Revenue, (US\$, Mn),

2023-2028

Table 28. By Country - Middle East & Africa Inactivated Vaccine Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Inactivated Vaccine Revenue, (US\$, Mn), 2023-2028

Table 30. Astellas Pharma(Japan) Corporate Summary

Table 31. Astellas Pharma(Japan) Inactivated Vaccine Product Offerings

Table 32. Astellas Pharma(Japan) Inactivated Vaccine Revenue (US\$, Mn), (2017-2022)

Table 33. CSL Limited(Australia) Corporate Summary

Table 34. CSL Limited(Australia) Inactivated Vaccine Product Offerings

Table 35. CSL Limited(Australia) Inactivated Vaccine Revenue (US\$, Mn), (2017-2022)

Table 36. Emergent BioSolutions(U.S.) Corporate Summary

Table 37. Emergent BioSolutions(U.S.) Inactivated Vaccine Product Offerings

Table 38. Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue (US\$, Mn), (2017-2022)

Table 39. GlaxoSmithKline(U.K.) Corporate Summary

Table 40. GlaxoSmithKline(U.K.) Inactivated Vaccine Product Offerings

Table 41. GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue (US\$, Mn), (2017-2022)

Table 42. Johnson & Johnson(U.S.) Corporate Summary

Table 43. Johnson & Johnson(U.S.) Inactivated Vaccine Product Offerings

Table 44. Johnson & Johnson(U.S.) Inactivated Vaccine Revenue (US\$, Mn), (2017-2022)

Table 45. MedImmune(U.S.) Corporate Summary

Table 46. MedImmune(U.S.) Inactivated Vaccine Product Offerings

Table 47. MedImmune(U.S.) Inactivated Vaccine Revenue (US\$, Mn), (2017-2022)

Table 48. Merck & Co(U.S.) Corporate Summary

Table 49. Merck & Co(U.S.) Inactivated Vaccine Product Offerings

Table 50. Merck & Co(U.S.) Inactivated Vaccine Revenue (US\$, Mn), (2017-2022)

Table 51. Pfizer(U.S.) Corporate Summary

Table 52. Pfizer(U.S.) Inactivated Vaccine Product Offerings

Table 53. Pfizer(U.S.) Inactivated Vaccine Revenue (US\$, Mn), (2017-2022)

Table 54. Sanofi Pasteur(France) Corporate Summary

Table 55. Sanofi Pasteur(France) Inactivated Vaccine Product Offerings

Table 56. Sanofi Pasteur(France) Inactivated Vaccine Revenue (US\$, Mn), (2017-2022)

Table 57. Serum Institute of India Pvt(India) Corporate Summary

Table 58. Serum Institute of India Pvt(India) Inactivated Vaccine Product Offerings

Table 59. Serum Institute of India Pvt(India) Inactivated Vaccine Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Inactivated Vaccine Segment by Type in 2021
- Figure 2. Inactivated Vaccine Segment by Application in 2021
- Figure 3. Global Inactivated Vaccine Market Overview: 2020
- Figure 4. Key Caveats
- Figure 5. Global Inactivated Vaccine Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Inactivated Vaccine Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Inactivated Vaccine Revenue in 2021
- Figure 8. By Type - Global Inactivated Vaccine Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Inactivated Vaccine Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Inactivated Vaccine Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Inactivated Vaccine Revenue Market Share, 2017-2028
- Figure 12. US Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Inactivated Vaccine Revenue Market Share, 2017-2028
- Figure 16. Germany Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Inactivated Vaccine Revenue Market Share, 2017-2028
- Figure 24. China Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 28. India Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 29. By Country - South America Inactivated Vaccine Revenue Market Share, 2017-2028
- Figure 30. Brazil Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028
- Figure 31. Argentina Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Inactivated Vaccine Revenue Market Share, 2017-2028

Figure 33. Turkey Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Inactivated Vaccine Revenue, (US\$, Mn), 2017-2028

Figure 37. Astellas Pharma(Japan) Inactivated Vaccine Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. CSL Limited(Australia) Inactivated Vaccine Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Johnson & Johnson(U.S.) Inactivated Vaccine Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. MedImmune(U.S.) Inactivated Vaccine Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Merck & Co(U.S.) Inactivated Vaccine Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Pfizer(U.S.) Inactivated Vaccine Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Sanofi Pasteur(France) Inactivated Vaccine Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Serum Institute of India Pvt(India) Inactivated Vaccine Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Inactivated Vaccine Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/I54065E0468BEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I54065E0468BEN.html>